Friday, June 26, 2009

Nuclea Biotechnologies offering $3M in stock sale

By Mass High Tech staff

Nuclea Biotechnologies LLC, a genomic research firm in Pittsfield, has sold about $1 million of a $3 million stock offering, according to a filing with the U.S. Securities and Exchange Commission.

As of the filing, eight unnamed buyers have partaken in the stock offering.

At the time of writing, Nuclea Biotechnologies officials were not available to confirm the offering nor discuss the plan for the additional funding.

The company aims to find biomarkers and gene or protein expression profiles that relate to cancer. Nuclea also researches therapeutics in the field of inflammation. The company maintains a biorepository and develops its tissue microarray technology, described as tissue samples that collect raw gene sequence information.

According to a release from the company last November, Nuclea moved the majority of its research and scientific positions to Worcester, where the company has a collaboration with Clark University.